Genmab — Oktober 2025
-
11 aug var kun for de der ventede på bekræftelse af tendensen. Jeg skrev her på pi ca 3/4 juli at nu var opgangen cementeret. Vendingen skete allerede klart i april, men vi måtte vente på at se om det holdt en tid derefter. Den soleklare bekræftelse kom 3 juli da bunden af trenden holdt. Købte lidt Bull i april, og gik all in 4 juli. Både supplering og mange Bull. Ingen grund til at vente på en alt alt for langsom bekræftelse fra TÁ.
-
Lundbeck to showcase amlenetug Phase 3 MASCOT trial design in Multiple System Atrophy at the International Congress of Parkinson's Disease and Movement Disorders
2025 https://www.prnewswire.com/news-releases/lundbeck-to-showcase-amlenetug-phase-3-mascot-trial-design-in-multiple-system-atrophy-at-the-international-congress-of-parkinsons-disease-and-movement-disorders-2025-302573439.html -
Som en skrev.. vi var ikke steget på dette opkøb for nogle måneder siden. Sentiment omkring Gmab er ændret og vi bliver derfor belønnet. Jeg har selv reddet med på Bull, med 4 x køb siden Feb. En tand for tidligt men fik derefter købt i April og 2 gange omkring 1300. En tiltrængt fest efter år med nedgang i kursen. Så enig i at opturen self ikke er startet med opkøbet.
-
Bolt not doing too well... Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
https://natlawreview.com/press-releases/bolt-biotherapeutics-provides-update-bdc-4182-and-extends-cash-runway-2027 If one of the programs Genmab is working on with them, it would be cheap to buy them at this market cap... -
Enig Lahn. Jeg havde faktisk selv regnet med et dyk i kursen pga. opkøbet, og det kom jo faktisk også, men som du skriver så er stemningen vendt, og nu
bliver nyheder positivt modtaget. -
Aktier/middag: Novo og sundhedsaktierne er i hopla - Genmab passerer 2000 kr. https://proinvestor.com/investornyt/1367306/aktier-middag-novo-og-sundhedsaktierne-er-i-hopla-genmab-passerer-2000-kr
-
The world market for head and neck cancer was estimated at approximately $2.27 billion in 2024, and projected to reach $6.25 billion by 2033 https://www.insideprecisionmedicine.com/topics/oncology/genmab-to-acquire-merus-and-novel-advanced-cancer-prospect-for-8-billion/
-
Er tilliden til at selskabet kan håndtere fremtiden trods l stede,og det er den nu, er P/E 30 billigt, hvis man kigger fremad. OG det gør man, hvis tilliden til fremtiden er etableret og forankret.
-
HC Wainwright has raised its price target for Genmab A/S (NASDAQ:GMAB) from $36.00 to $40.00, suggesting a potential upside of 25.48% from the stock's previous close and maintaining a "buy" rating. https://www.marketbeat.com/instant-alerts/hc-wainwright-issues-positive-forecast-for-genmab-as-nasdaqgmab-stock-price-2025-10-02/
-
Flere dages kursstigninger - er trenden positiv? Genmab, Novo Nordisk, Zealand Pharma, Gubra . Kort video: https://proinvestor.com/boards/128686
Put Wainwright in the Søg box and you should see roughly what they didHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind